SCM To Manufacture Onco-Drug for SEP

Speciality European Pharma (SEP) and SCM Pharma have entered a manufacturing development agreement for the development and validation of the manufacturing and product testing processes at SCM’s UK-based facility. SEP initiated the transfer of the commercial supply of its oncology product Plenaxis to SCM Pharma. Once the development is complete, SCM is expected to be the exclusive production partner for the vial filling of SEP’s hormonal product for the treatment of advanced and metastatic prostate cancer. SCM will then supply the licensed product in Germany and across Europe. The product is a highly potent dry powder substance that will be filled in a highly contained environment and presented in terminally sterilized vial.

Tim Record, vice president of operations at Speciality European Pharma, said, “SCM Pharma has an excellent reputation in the industry and high quality standards, which makes them an ideal partner for a specialist pharma company such as SEP. We feel SCM has the right facilities, expertise and approach to meet our current and forecasted product supply needs and we look forward to building a long-term relationship with them.”

Dianne Sharp, managing director at SCM Pharma, commented, “The project with SEP is a real milestone for our business in that it should lead to the securing of another long-term commercial contract and also further reinforces our position of assisting pharmaceutical companies developing or requiring supply of cancer products.”